47
Participants
Start Date
November 4, 2015
Primary Completion Date
May 22, 2018
Study Completion Date
May 22, 2018
Rivaroxaban (Xarelto, BAY59-7939
Single dose of reconstituted rivaroxaban granules
University of Semmelweis/ Semmelweis Egyetem, Budapest
UZ Leuven Gasthuisberg, Leuven
A.O.U. Città della Salute e della Scienza di Torino, Turin
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
Turun yliopistollinen keskussairaala, kantasairaala, Turku
Hospital General Universitario Gregorio Marañón, Madrid
Carolinas Healthcare System, Charlotte
Hôpital Arnaud de Villeneuve - Montpellier, Montpellier
A.O. di Padova, Padua
Riley Hospital For Children, Indianapolis
Arkansas Children's Hospital, Little Rock
Hopital Necker les enfants malades - Paris, Paris
Children's Hospital Oakland, Oakland
Nationwide Children's Hospital, Columbus
University of Alberta Hospital, Edmonton
McMaster Children's Hospital, Hamilton
Children's Hospital of Eastern Ontario, Ottawa
Hospital for Sick Children, Toronto
HUS Lastenklinikka, HUS
Hospital de Sant Joan de Déu, Esplugues de Llobregat
Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY